AstraZeneca PLC
AZN
$190.29
-$2.21-1.15%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.74B | 58.13B | 56.50B | 54.98B | 54.07B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.74B | 58.13B | 56.50B | 54.98B | 54.07B |
| Cost of Revenue | 10.75B | 9.73B | 10.02B | 9.65B | 9.64B |
| Gross Profit | 47.99B | 48.40B | 46.48B | 45.33B | 44.44B |
| SG&A Expenses | 20.07B | 19.23B | 19.32B | 19.40B | 19.45B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -222.00M | -313.00M | -249.00M | -237.00M | -190.00M |
| Total Operating Expenses | 44.45B | 42.22B | 42.15B | 41.37B | 41.14B |
| Operating Income | 14.29B | 15.91B | 14.35B | 13.61B | 12.93B |
| Income Before Tax | 12.40B | 11.44B | 10.02B | 9.29B | 8.69B |
| Income Tax Expenses | 2.17B | 2.04B | 1.72B | 1.51B | 1.65B |
| Earnings from Continuing Operations | 10.23K | 9.40K | 8.30K | 7.78K | 7.04K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -8.00M | -5.00M | -7.00M | -10.00M | -6.00M |
| Net Income | 10.23B | 9.40B | 8.30B | 7.77B | 7.04B |
| EBIT | 14.29B | 15.91B | 14.35B | 13.61B | 12.93B |
| EBITDA | 19.28B | 20.42B | 19.13B | 18.28B | 17.57B |
| EPS Basic | 6.59 | 6.06 | 5.35 | 5.01 | 4.54 |
| Normalized Basic EPS | 5.24 | 5.88 | 5.28 | 4.99 | 4.70 |
| EPS Diluted | 6.54 | 6.02 | 5.31 | 4.97 | 4.50 |
| Normalized Diluted EPS | 5.20 | 5.84 | 5.24 | 4.95 | 4.67 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.24B | 6.24B | 6.24B | 6.25B | 6.24B |
| Dividend Per Share | 3.20 | 3.13 | 3.13 | 3.10 | 3.10 |
| Payout Ratio | 48.59% | 52.89% | 59.51% | 63.60% | 65.80% |